In 2022, prostate cancer (PCa) is estimated to be the most commonly diagnosed cancer in men in the United States—almost 270,000 American men are estimated to be diagnosed with PCa in 2022. This review compares and contrasts in vivo models of PCa with regards to the altered genes, signaling pathways, and stages of tumor progression associated with each model. The main type of model included in this review are genetically engineered mouse models, which include conditional and constitutive knockout model. 2D cell lines, 3D organoids and spheroids, xenografts and allografts, and patient derived models are also included. The major applications, advantages and disadvantages, and ease of use and cost are unique to each type of model, but they all make it easier to translate the tumor progression that is seen in the mouse prostate to the human prostate. Although both human and mouse prostates are androgen-dependent, the fact that the native, genetically unaltered prostate in mice cannot give rise to carcinoma is an especially critical component of PCa models. Thanks to the similarities between the mouse and human genome, our knowledge of PCa has been expanded, and will continue to do so, through models of PCa.
In 2022, prostate cancer (PCa) is estimated to be the most commonly diagnosed cancer in men in the United States – almost 270,000 American men are estimated to be diagnosed with PCa in 2022 [1]. This review compares and contrasts in vivo models of PCa with regards to the altered genes, signaling pathways, and stages of tumor progression associated with each model. The main type of model included in this review are genetically engineered mouse models, which include conditional and constitutive knockout model. 2D cell lines, 3D organoids and spheroids, xenografts and allografts, and patient derived models are also included. The major applications, advantages and disadvantages, and ease of use and cost are unique to each type of model, but they all make it easier to translate the tumor progression that is seen in the mouse prostate to the human prostate. Although both human and mouse prostates are androgen-dependent, the fact that the native, genetically unaltered prostate in mice cannot give rise to carcinoma is an especially critical component of PCa models. Thanks to the similarities between the mouse and human genome, our knowledge of PCa has been expanded, and will continue to do so, through models of PCa.
This study aims to elucidate the role of Abelson interactor 1 (Abi1), a key protein in the WAVE regulatory complex, in mammary carcinogenesis and metastasis. Breast cancer is the second-leading cause of mortality in women in the United States with an estimated ~200,000 new cases and over 40,000 deaths this year. Despite current treatment modalities, breast cancer patients often relapse after only a few years of treatment thus emphasizing the need for better therapeutic targets. Abi1 is an adaptor protein mainly associated with the WAVE (Wiscott-Aldrich syndrome protein family verprolin homologous) regulatory complex and Arp2/3 (Actin-related proteins 2 and 3)-mediated actin cytoskeleton remodeling. Our bioinformatic and gene expression analyses of human tumor data indicates that Abi1 is frequently upregulated in invasive breast cancers, is associated with poor survival, and may promote an aggressive breast tumor phenotype. Downregulation of Abi1 also abrogates motility and invasion of breast cancer cells, most likely through inactivation of both Src and PI3 kinase as well as certain matrix metalloproteases. We therefore hypothesize that Abi1 positively regulates breast tumor progression and invasion through dysregulation of these cell signaling pathways. To determine the role of Abi1 in breast tumor progression, we used a Cre-lox system to conditionally delete Abi1 in the mammary tissue of Polyoma Middle T (PyMT) breast cancer mice. Abi1 knockout (KO) and control mice were palpated bi-weekly to determine tumor latency and tumors were measured with a caliper to determine total tumor burden. We are currently analyzing changes in tumor kinetics as a result of conditional Abi1 knockout in the mammary epithelium of PyMT mice. Our preliminary studies of indicate slowed tumor growth in Abi1 KO PyMT mice. Western blot analyses of Abi1 KO mammary tumors indicate concomitant loss of WAVE complex proteins supporting our previous findings that WAVE complex integrity is dependent on Abi1. Most interestingly, Abi1 null PyMT mice exhibit significantly reduced incidence of lung metastasis, supporting our hypothesis that Abi1 promotes invasion by breast cancer cells. In summary, Abi1 loss leads to reduction of lung metastasis in PyMT mice, possibly through inactivation of key cell signaling and proliferation pathways such as Src and PI3 kinase. This work will establish Abi1 as a potential prognostic marker and therapeutic target in metastatic breast cancer. Citation Format: Angelina Regua, Isabelle Bichindaritz, Tiffany Caza, Julie White, Robert Adamiecki, Mira Krendel, Gennady Bratslavsky, Leszek Kotula. Loss of Abi1 abrogates lung metastasis in the PyMT mouse model of breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3404. doi:10.1158/1538-7445.AM2017-3404
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.